Helicobacter pylori-Derived Outer Membrane Vesicles Promote Hepatocellular Carcinoma Cell Proliferation with PI3K/AKT/mTOR Activation and Cyclin D1 Upregulation
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27219573 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Jun-Peng Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Cyclin D1, TOR Serine-Threonine Kinases, Helicobacter pylori, Phosphatidylinositol 3-Kinases. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Accumulating evidence suggests an association between Helicobacter pylori infection and liver diseases; however, it remains unclear whether H. pylori or its extracellular products directly influence hepatocellular carcinoma (HCC) biology. Here, we examined the effects of viable H. pylori, sterile H. pylori-conditioned supernatant (Hp-CS), and isolated H. pylori-derived outer membrane vesicles (Hp-OMVs) on HCC cells. H. pylori adhered to and invaded Huh7 and Hepa1-6 cells, increased Cyclin D1 expression, and enhanced the growth of tumors derived from bacteria-exposed Hepa1-6 cells in immunocompetent C57BL/6J mice. Hp-CS increased HCC cell metabolic activity, colony formation, migration, and invasion. Hp-OMVs were characterized by transmission electron microscopy and nanoparticle tracking analysis. Exposure to Hp-OMVs increased HCC cell metabolic activity, colony formation, cell-cycle progression, and tumor growth in a syngeneic mouse model. Hp-OMVs also increased PI3K, AKT, and mTOR phosphorylation and elevated Cyclin D1 expression. The PI3K inhibitor LY294002 attenuated these molecular changes and reduced Hp-OMV-induced cell-cycle progression and colony formation. These findings show that H. pylori and its extracellular products promote proliferation-associated phenotypes in experimental HCC models. Hp-OMVs are biologically active extracellular components of H. pylori, and pharmacological inhibition supports the involvement of PI3K/AKT/mTOR signaling and Cyclin D1 upregulation in their growth-promoting effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.
- Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.
- Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.
ORCID-Profile: Jun-Peng Zhou
Förderung
- 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University
Zitieren
APA
Zhou, J. P., Song, X. N., Li, J., Huang, H., Chen, H., Tang, H., & Li, H. (2026). Helicobacter pylori-Derived Outer Membrane Vesicles Promote Hepatocellular Carcinoma Cell Proliferation with PI3K/AKT/mTOR Activation and Cyclin D1 Upregulation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27219573
Vancouver
Zhou JP, Song XN, Li J, Huang H, Chen H, Tang H, et al. Helicobacter pylori-Derived Outer Membrane Vesicles Promote Hepatocellular Carcinoma Cell Proliferation with PI3K/AKT/mTOR Activation and Cyclin D1 Upregulation. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27219573
BibTeX
@article{Zhou2026,
author = {Zhou, Jun-Peng and Song, Xiao-Na and Li, Jiao and Huang, Hui and Chen, Han and Tang, Hong and Li, Hong},
title = {Helicobacter pylori-Derived Outer Membrane Vesicles Promote Hepatocellular Carcinoma Cell Proliferation with PI3K/AKT/mTOR Activation and Cyclin D1 Upregulation},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27219573}
}
EUVIMED